Edison Investment Research - Pharmaceutical & healthcare - Sunesis Pharmaceuticals: On the YE FY17 conference call, the company provided revised guidance on the dosing portion of its ongoing Phase Ib/II study of vecabrutinib (SNS-062) in chronic lymphocytic leukemia (CLL) and other B-cell cancers. The final dose is expected to be reached in fall 2018 (revised from mid-2018) due to an on-protocol expansion of the second (50mg) dosing cohort because of a dose-limiting adverse event (AE). At this time we do not consider this delay or the AE to be material to the success of the program.
ISIN: US8673287004
Original Article: Sunesis Pharmaceuticals (SNSS) - A slight delay
NEXT ARTICLE